比较伊诺莫单抗与常规治疗用于激素耐药急性GVHD的3期随机试验
这项3期随机、开放标签、多中心试验纳入100例激素难治性急性GVHD成人患者,随机接受伊诺莫单抗(49例)或常规治疗(对照组用抗胸腺细胞球蛋白[ATG],51例)。1年无改变基线分配治疗的总体生存主要终点未达到:伊诺莫单抗组14例(28.5%)vs ATG组11例(21.5%),风险比0.874(P=.28)。两组不良事件相似,伊诺莫单抗组病毒感染较少。
要点
- 伊诺莫单抗组1年主要终点达标14例(28.5%),ATG组11例(21.5%),HR 0.874(P=.28),未达统计学显著。
- 随访至少1年,伊诺莫单抗组死亡26例(53%),ATG组死亡31例(60%)。
- 两组不良事件相似,伊诺莫单抗组病毒感染少于ATG组。
核心结论
- 该3期随机试验的主要终点未达到,无统计学显著效应,确认需要开发更有效的急性GVHD治疗方法。
研究设计与样本
- 3期随机、开放标签、多中心试验,比较伊诺莫单抗与常规治疗(对照组用抗胸腺细胞球蛋白[ATG])在成人激素难治性急性GVHD患者中的效果。
- 共100例患者随机分组:伊诺莫单抗组49例,ATG组51例。
- 主要目标为评估1年总体生存且不改变基线分配治疗。
主要发现
- 主要终点达标:伊诺莫单抗组14例(28.5%)vs ATG组11例(21.5%),风险比0.874(P=.28)。
- 随访至少1年,伊诺莫单抗组死亡26例(53%),ATG组死亡31例(60%)。
- 两组不良事件相似,伊诺莫单抗组病毒感染少于ATG组。
局限性
- 该3期随机试验的主要终点未达到,无统计学显著效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment of steroid-resistant acute graft-versus-host disease (GVHD) remains an unmet clinical need. Inolimomab, a monoclonal antibody to CD25, has shown encouraging results in phase 2 trials. This phase 3 randomized, open-label, multicenter trial compared inolimomab vs usual care in adult patients with steroid-refractory acute GVHD. Patients were randomly selected to receive treatment with inolimomab or usual care (the control group was treated with antithymocyte globulin [ATG]). The primary objective was to evaluate overall survival at 1 year without changing baseline allocated therapy. A total of 100 patients were randomly placed: 49 patients in the inolimomab arm and 51 patients in the ATG arm. The primary criteria were reached by 14 patients (28.5%) in the inolimomab and 11 patients (21.5%) in the ATG arms, with a hazard ratio of 0.874 (P = .28). With a minimum follow-up of 1 year, 26 (53%) and 31 (60%) patients died in the inolimomab and ATG arms, respectively. Adverse events were similar in the 2 arms, with fewer viral infections in the inolimomab arm compared with the ATG arm. The primary end point of this randomized phase 3 trial was not achieved. The lack of a statistically significant effect confirms the need for development of more effective treatments for acute GVHD. This trial is registered to https://www.clinicaltrialsregister.eu/ctr-search/search as EUDRACT 2007-005009-24.
引用
- Socié G, Vigouroux S, Yakoub-Agha I, et al. A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD. Blood. 2016. PMID: 27899357. doi:10.1182/blood-2016-09-738625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。